NGM Biopharmaceuticals, Inc.

NasdaqGS:NGM Stock Report

Market Cap: US$135.2m

NGM Biopharmaceuticals Future Growth

Future criteria checks 2/6

NGM Biopharmaceuticals is forecast to grow earnings and revenue by 14.7% and 57.6% per annum respectively. EPS is expected to grow by 20.3% per annum. Return on equity is forecast to be -230.7% in 3 years.

Key information

14.7%

Earnings growth rate

20.3%

EPS growth rate

Pharmaceuticals earnings growth21.6%
Revenue growth rate57.6%
Future return on equity-230.7%
Analyst coverage

Low

Last updated12 Mar 2024

Recent future growth updates

Recent updates

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

Dec 19
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Oct 05
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Aug 09
Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Jun 27
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Apr 17
NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

Dec 20
We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Oct 17

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Jun 30

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Jun 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jun 15
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

May 09
Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

Apr 26

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Feb 21
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Nov 08
We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jul 09
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 06
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Mar 02
We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Update: NGM Biopharmaceuticals (NASDAQ:NGM) Stock Gained 56% In The Last Year

Jan 26
Update: NGM Biopharmaceuticals (NASDAQ:NGM) Stock Gained 56% In The Last Year

NGM Bio gives update on 2021 plans and data timeline

Jan 12

NGM Bio prices $125M share offering

Jan 06

NGM Biopharmaceuticals proposes $100M public offering

Jan 04

Earnings and Revenue Growth Forecasts

NasdaqGS:NGM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20269-90-88-464
12/31/20250-94-89-785
12/31/20240-98-77-693
12/31/20234-142-133-132N/A
9/30/202322-151-141-140N/A
6/30/202330-170-142-141N/A
3/31/202337-178-153-151N/A
12/31/202255-163-146-144N/A
9/30/202258-153-134-132N/A
6/30/202269-135-115-114N/A
3/31/202277-125-89-87N/A
12/31/202178-120-75-73N/A
9/30/202177-121-77-75N/A
6/30/202182-122-93-91N/A
3/31/202185-111-88-87N/A
12/31/202087-102-85-83N/A
9/30/202099-90-81-78N/A
6/30/202097-72-62-60N/A
3/31/2020102-54-50-48N/A
12/31/2019104-43-45-41N/A
9/30/2019120-13-22-20N/A
6/30/2019119-9-22-19N/A
3/31/2019116-5-22-15N/A
12/31/20181090-13-8N/A
9/30/201881-17-24-18N/A
6/30/201880-12-22-15N/A
3/31/201877-13-21-16N/A
12/31/201777-14-24-17N/A
12/31/201686-7N/A1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NGM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NGM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NGM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NGM's revenue (57.6% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: NGM's revenue (57.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NGM is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.